Online citations, reference lists, and bibliographies.
← Back to Search

Oral Delivery Of Diabetes Peptides - Comparing Standard Formulations Incorporating Functional Excipients And Nanotechnologies In The Translational Context.

H. R. Lakkireddy, M. Urmann, Melissa Besenius, U. Werner, T. Haack, Priscilla Brun, Jean Alié, Brigitte Illel, Laurent Hortala, R. Vogel, Didier Bazile
Published 2016 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
While some orally delivered diabetes peptides are moving to late development with standard formulations incorporating functional excipients, the demonstration of the value of nanotechnology in clinic is still at an early stage. The goal of this review is to compare these two drug delivery approaches from a physico-chemical and a biopharmaceutical standpoint in an attempt to define how nanotechnology-based products can be differentiated from standard oral dosage forms for oral bioavailability of diabetes peptides. Points to consider in a translational approach are outlined to seize the opportunities offered by a better understanding of both the intestinal barrier and of nano-carriers designed for oral delivery.
This paper references
10.1016/S0196-9781(01)00601-5
Distribution of pancreatic polypeptide and peptide YY
E. Ekblad (2002)
10.1016/J.ADDR.2004.06.001
Real-time multiple-particle tracking: applications to drug and gene delivery.
Junghae Suh (2005)
10.1016/j.ijpharm.2011.12.038
Antacid co-encapsulated polyester nanoparticles for peroral delivery of insulin: development, pharmacokinetics, biodistribution and pharmacodynamics.
Gaurav Sharma (2013)
10.1177/193229680900300323
Oral Insulin and Buccal Insulin: A Critical Reappraisal
L. Heinemann (2009)
10.1016/j.jacc.2008.11.008
Defining the role of basal and prandial insulin for optimal glycemic control.
E. Horton (2009)
A pharmaceutical composition of nanoparticles
투 호쉥 (2011)
10.3109/10837450.2013.867445
Quality by design approach to understand the process of optimization of iloperidone nanostructured lipid carriers for oral bioavailability enhancement
Leenata Mandpe (2015)
10.1007/978-1-60327-198-1_3
Considerations when submitting nanotherapeutics to FDA/CDER for regulatory review.
K. Tyner (2011)
10.1152/AJPREGU.1994.267.1.R178
Modulation of food intake by peripherally administered amylin.
J. Morley (1994)
Transepithelial Transport of Large Particles in Rat: a New Model for the Quantitative Study of Particle Uptake,
J. Limpanussorn (1998)
10.1016/0306-9877(91)90150-W
Amylin and insulin co-replacement therapy for insulin-dependent (type I) diabetes mellitus.
G. Cooper (1991)
10.1016/j.ijpharm.2013.06.051
Preparation, characterization, and evaluation in vivo of Ins-SiO₂-HP55 (insulin-loaded silica coating HP55) for oral delivery of insulin.
Xiuhua Zhao (2013)
10.18433/J3J88Q
Efficient Peroral Delivery of Insulin via Vitamin B12 Modified Trimethyl Chitosan Nanoparticles.
Zhiyang Ke (2015)
10.1016/J.JCONREL.2007.05.019
Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles.
K. Chalasani (2007)
10.1038/labinvest.2008.86
Yersinia pseudotuberculosis induces transcytosis of nanoparticles across human intestinal villus epithelium via invasin-dependent macropinocytosis
E. Ragnarsson (2008)
10.1016/j.biomaterials.2011.12.038
Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery.
Fang-Yi Su (2012)
10.2147/IJN.S19917
Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation
M. Niu (2011)
10.1016/j.biotechadv.2013.11.006
Techniques for physicochemical characterization of nanomaterials.
Ping-Chang Lin (2014)
10.1021/mp400685v
Mechanism study of cellular uptake and tight junction opening mediated by goblet cell-specific trimethyl chitosan nanoparticles.
J. Zhang (2014)
10.1038/35051587
A role for ghrelin in the central regulation of feeding
M. Nakazato (2001)
Arbit, «A single-blind, two period study to assess the safety and pharmacodynamics of an orally delivered GLP-1 analog (exenatide) in healthy subjects,
R. Eldor (2010)
10.1111/j.1464-5491.2004.01160.x
A novel per‐oral insulin formulation: proof of concept study in non‐diabetic subjects
M. Kidron (2004)
10.1016/j.ejpb.2015.03.002
Chip-based human liver-intestine and liver-skin co-cultures--A first step toward systemic repeated dose substance testing in vitro.
I. Maschmeyer (2015)
10.1016/j.ijpharm.2014.07.049
Preparation and characterization of PEG-coated silica nanoparticles for oral insulin delivery.
T. Andreani (2014)
10.1016/j.biomaterials.2012.09.051
Sodium caprate as an enhancer of macromolecule permeation across tricellular tight junctions of intestinal cells.
Susanne M. Krug (2013)
10.1016/J.JCONREL.2006.12.003
A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin.
K. Chalasani (2007)
10.1038/clpt.2008.35
Pharmacokinetics and Pharmacodynamic Effects of Oral GLP‐1 and PYY3‐36: A Proof‐of‐concept Study in Healthy Subjects
C. Beglinger (2008)
10.1021/acs.jmedchem.5b00726
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
J. Lau (2015)
10.1172/JCI101175
EFFECTIVENESS OF PER-ORAL INSULIN IN HUMAN DIABETES.
J. Murlin (1940)
10.2147/CE.S16359
Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes
Edward C. Chao (2012)
Intestinal absorption of PLAGA microspheres in the rat.
C. Damgé (1996)
10.1016/j.addr.2013.05.009
Multiphase flow microfluidics for the production of single or multiple emulsions for drug delivery.
Chun-Xia Zhao (2013)
10.1016/j.biomaterials.2008.12.066
In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery.
K. Sonaje (2009)
10.2147/IJGM.S26889
Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus
C. Morello (2011)
Oral insulin delivery by means of solid lipid nanoparticles
B. Sarmento (2007)
Relationship between drug effects and particle size of insulin-loaded bioadhesive microspheres.
Yan Pan (2002)
10.1002/JCB.240550004
Molecular physiology of amylin
R. Pittner (1994)
10.1124/pr.108.000604
The Role of Incretins in Glucose Homeostasis and Diabetes Treatment
Wook Kim (2008)
10.1248/BPB.B13-00591
Permeability of exendin-4-loaded chitosan nanoparticles across MDCK cell monolayers and rat small intestine.
M. Wang (2014)
10.1016/j.nano.2013.08.003
Parallel microfluidic synthesis of size-tunable polymeric nanoparticles using 3D flow focusing towards in vivo study.
Jong-Min Lim (2014)
10.1016/j.ijpharm.2013.11.028
Enhanced oral absorption of insulin-loaded liposomes containing bile salts: a mechanistic study.
Mengmeng Niu (2014)
10.1007/s11095-014-1513-1
The Glucose-Lowering Potential of Exenatide Delivered Orally via Goblet Cell- Targeting Nanoparticles
X. Li (2014)
10.1021/JS970124I
Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin.
C. Damgé (1997)
10.1016/j.ejpb.2015.01.014
Steric and interactive barrier properties of intestinal mucus elucidated by particle diffusion and peptide permeation.
M. Boegh (2015)
10.1016/S0939-6411(00)00084-9
Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake?
T. Jung (2000)
10.1038/nmat2442
Understanding biophysicochemical interactions at the nano-bio interface.
A. Nel (2009)
10.1002/ZAAC.201300604
Functionalized Mesoporous Silica Nanoparticles for Glucose- and pH-Stimulated Release of Insulin†
Rachit Jain (2014)
10.1126/scitranslmed.3007049
Transepithelial Transport of Fc-Targeted Nanoparticles by the Neonatal Fc Receptor for Oral Delivery
Eric M. Pridgen (2013)
10.1016/J.JCONREL.2006.08.013
Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach.
A. des Rieux (2006)
10.1021/ar200234q
pH-responsive nanoparticles shelled with chitosan for oral delivery of insulin: from mechanism to therapeutic applications.
H. Sung (2012)
10.1016/j.regpep.2010.05.008
Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes
U. Werner (2010)
10.1056/NEJMOA012908
Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery.
D. Cummings (2002)
10.1016/j.jconrel.2010.04.008
Translational considerations for cancer nanomedicine.
S. Stern (2010)
10.1007/s00125-013-2923-z
Differences in metabolic and mitogenic signalling of insulin glargine and insulin aspart B10 in rats
N. Tennagels (2013)
10.1016/J.IJPHARM.2005.01.018
Investigation of lectin-modified insulin liposomes as carriers for oral administration.
N. Zhang (2005)
10.1517/17425247.5.1.45
Nanoparticle strategies for the oral delivery of insulin
C. Damgé (2008)
10.2337/diab.17.10.625
Absorption of Insulin from the Human Small Intestine
C. W. Crane (1968)
10.1021/mp500809f
Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs.
J. Wang (2015)
10.1016/j.biomaterials.2010.05.042
Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: Oral delivery using pH-responsive nanoparticles vs. subcutaneous injection.
K. Sonaje (2010)
10.1002/jps.21347
Nanoparticulate biopolymers deliver insulin orally eliciting pharmacological response.
C. Reis (2008)
10.1016/S0378-5173(01)00579-8
Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin: studies in the rat.
M. Kisel (2001)
10.1073/PNAS.84.10.3434
Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line.
D. Drucker (1987)
10.1177/1932296814529988
Oral Insulin Reloaded
E. Zijlstra (2014)
10.1111/j.1463-1326.2011.01546.x
Preparation, characterization and in vivo evaluation of pH‐sensitive oral insulin‐loaded poly(lactic‐co‐glycolicacid) nanoparticles
J. Yang (2012)
10.1021/BM049312A
Preparation of nanoparticles composed of chitosan/poly-gamma-glutamic acid and evaluation of their permeability through Caco-2 cells.
Y. Lin (2005)
10.1016/S0169-409X(00)00123-X
Polysaccharide colloidal particles as delivery systems for macromolecules.
K. Janes (2001)
10.1016/j.bbrc.2015.08.023
Regulatory aspects on nanomedicines.
V. Sainz (2015)
10.1248/CPB.58.1195
Preparation of gel-core-solid lipid nanoparticle: a novel way to improve the encapsulation of protein and peptide.
R. Yang (2010)
10.1016/j.biomaterials.2011.10.075
Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport.
Y. Jin (2012)
10.1038/nrd4363
Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies
S. Mitragotri (2014)
10.1186/1556-276X-7-299
Novel preparation of PLGA/HP55 nanoparticles for oral insulin delivery
Z. M. Wu (2012)
10.1042/BJ3340685
MUC5B is a major gel-forming, oligomeric mucin from human salivary gland, respiratory tract and endocervix: identification of glycoforms and C-terminal cleavage.
C. Wickström (1998)
10.1016/J.JCONREL.2006.10.023
Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats.
C. Damgé (2007)
10.1016/J.IJPHARM.2006.07.026
Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin.
N. Zhang (2006)
10.1016/J.JCONREL.2005.02.025
Stability of insulin during the erosion of poly(lactic acid) and poly(lactic-co-glycolic acid) microspheres.
M. Ibrahim (2005)
10.1007/s11095-013-1280-4
Development of 2D and 3D Mucus Models and Their Interactions with Mucus-Penetrating Paclitaxel-Loaded Lipid Nanocapsules
Anne-Claire Groo (2013)
10.1016/j.biomaterials.2011.03.056
Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening.
Tzyy-Harn Yeh (2011)
10.1210/JC.2002-021545
Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.
O. Kolterman (2003)
10.1021/JM00021A014
Microsphere formation in a series of derivatized alpha-amino acids: properties, molecular modeling, and oral delivery of salmon calcitonin.
A. Leone-Bay (1995)
10.1016/j.jconrel.2013.05.031
Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan.
Sukyung Ahn (2013)
10.1016/j.ijpharm.2014.06.012
Microfluidics-assisted engineering of polymeric microcapsules with high encapsulation efficiency for protein drug delivery.
Jenni Pessi (2014)
10.1016/j.addr.2009.03.005
In vitro assessments of nanomaterial toxicity.
Clinton F Jones (2009)
10.1016/0378-5173(91)90287-X
An estimate of turnover time of intestinal mucus gel layer in the rat in situ loop
C. Lehr (1991)
Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas.
J. Eng (1992)
10.1038/nnano.2012.168
Microfluidic technologies for accelerating the clinical translation of nanoparticles.
P. Valencia (2012)
10.1016/j.nano.2013.07.011
Biotinylated liposomes as potential carriers for the oral delivery of insulin.
X. Zhang (2014)
Arbit, «A single-blind, two period study to assess the safety and pharmacodynamics of an orally delivered GLP-1 analog (exenatide) in healthy subjects,
R. Eldor (2010)
10.1016/J.CARBPOL.2006.01.001
Protonation constants of chitosan with different molecular weight and degree of deacetylation
Q. Wang (2006)
10.1016/j.ejpb.2014.01.001
Property profiling of biosimilar mucus in a novel mucus-containing in vitro model for assessment of intestinal drug absorption.
M. Boegh (2014)
10.1042/BJ2390147
Electron microscopy of cervical, gastric and bronchial mucus glycoproteins.
J. Sheehan (1986)
10.1016/J.EJPB.2014.10.008
A head-to-head multi-parametric high content analysis of a series of medium chain fatty acid intestinal permeation enhancers in Caco-2 cells.
D. Brayden (2014)
10.1016/j.bmcl.2013.05.022
Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity.
M. Lorenz (2013)
Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes,
U. Werner (2010)
10.3109/13813455.2012.754474
The metabolic and mitogenic properties of basal insulin analogues
N. Tennagels (2013)
10.1006/BBRC.2000.4038
Expression of specific markers and particle transport in a new human intestinal M-cell model.
E. Gullberg (2000)
10.1073/pnas.0608611104
Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus
S. Lai (2007)
10.1124/jpet.106.107847
Identification of Cell Adhesion Molecules in the Human Follicle-Associated Epithelium That Improve Nanoparticle Uptake into the Peyer's Patches
E. Gullberg (2006)
10.1111/j.1463-1326.2009.01150.x
Oral insulin – a review of current status
H. Iyer (2010)
10.1016/j.jconrel.2015.05.270
Enhanced paracellular transport of insulin can be achieved via transient induction of myosin light chain phosphorylation
Alistair Taverner (2015)
10.1016/j.maturitas.2012.05.014
Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective.
A. C. Hunter (2012)
10.1016/j.addr.2016.02.004
Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials.
T. A. Aguirre (2016)
10.2337/diab.37.2.246
New Approach for Oral Administration of Insulin With Polyalkylcyanoacrylate Nanocapsules as Drug Carrier
C. Damgé (1988)
10.1021/mp500776a
Interaction with Mixed Micelles in the Intestine Attenuates the Permeation Enhancing Potential of Alkyl-Maltosides.
K. Gradauer (2015)
Galehassadi, «Preparation of Ionic Liquid Functionalized Silica Nanoparticles for Oral Drug Delivery,
M. Mahkam (2012)
10.1080/02652040110081406
The effect of oral absorption enhancers on the in vivo performance of insulin-loaded poly(ethylcyanoacrylate) nanospheres in diabetic rats
M. A. Radwan (2002)
Shard, «Emerging Techniques for Submicrometer Particle Sizing Applied to St ber Silica,
N. ell (2012)
10.1002/JPS.20750
Preparation of insulin loaded PLGA-Hp55 nanoparticles for oral delivery.
F. Cui (2007)
10.1248/CPB.44.235
Instability of bovine insulin in poly(lactide-co-glycolide) (PLGA) microspheres.
T. Uchida (1996)
10.1001/ARCHINTE.1985.00360070158027
Physiology of the splanchnic circulation.
D. Parks (1985)
10.1016/j.ijpharm.2012.06.054
Thiolated Eudragit nanoparticles for oral insulin delivery: preparation, characterization and in vivo evaluation.
Yajie Zhang (2012)
10.1111/cbdd.12055
The Future of Peptide‐based Drugs
D. Craik (2013)
10.2337/dc09-1807
Oral Insulin: A Comparison With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes
C. Kapitza (2010)
10.1021/la301351k
Emerging techniques for submicrometer particle sizing applied to Stöber silica.
Nia C. Bell (2012)
10.1016/0169-409X(88)90022-1
Some biological issues in oral, controlled drug delivery
P. Gruber (1987)
10.3109/9781420081831-45
Recommendations for Toxicological Evaluation of Nanoparticle Medicinal Products
Jean-Roger Claude (2009)
10.1016/j.nano.2009.04.007
Preparation and characterization of insulin nanoparticles using chitosan and Arabic gum with ionic gelation method.
M. R. Avadi (2010)
10.1016/j.colsurfb.2012.10.043
Preparation of amphiphilic hollow carbon nanosphere loaded insulin for oral delivery.
M. Ganeshkumar (2013)
10.1016/j.biomaterials.2012.07.063
Size-dependent absorption mechanism of polymeric nanoparticles for oral delivery of protein drugs.
Chunbai He (2012)
10.1177/193229680900300627
Hepatic-Directed Vesicle Insulin: A Review of Formulation Development and Preclinical Evaluation
W. Geho (2009)
Geho, «Orally bioavailable lipid-based constructs
B. J. Lau et (2015)
10.1016/0014-5793(76)80016-6
Oral administration of insulin by encapsulation within liposomes
H. M. Patel (1976)
10.1007/s11095-011-0634-z
The Counterbalanced Effect of Size and Surface Properties of Chitosan-Coated poly(isobutylcyanoacrylate) Nanoparticles on Mucoadhesion Due to Pluronic F68 Addition
B. Petit (2011)
10.1038/35038090
Ghrelin induces adiposity in rodents
M. Tschöp (2000)
10.7573/dic.212278
Clinical factors, including All Patient Refined Diagnosis Related Group severity, as predictors of early rehospitalization after COPD exacerbation
M. Roberts (2015)
10.2337/DIACARE.25.4.724
A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
F. Whitehouse (2002)
10.5772/52265
Oral Delivery of Insulin: Novel Approaches
Amani M. Elsayed (2012)
10.4236/JBNB.2012.33038
Preparation of Ionic Liquid Functionalized Silica Nanoparticles for Oral Drug Delivery
Mehrdad Mahkam (2012)
10.1002/BDD.1803
Mechanistic analysis of solute transport in an in vitro physiological two‐phase dissolution apparatus
P. Langguth (2012)
10.1016/S0168-3659(97)00204-6
The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins.
A. Bernkop-Schnürch (1998)
10.1074/jbc.M309026200
Enhanced Viscoelasticity of Human Cystic Fibrotic Sputum Correlates with Increasing Microheterogeneity in Particle Transport*
M. Dawson (2003)
10.1016/S0140-6736(76)91209-5
HYPOGLYCÆMIC EFFECT OF LIPOSOME-ENTRAPPED INSULIN ADMINISTERED INTRAGASTRICALLY INTO RATS
G. Dapergolas (1976)
Plum-Mörschel, «Oral Insulin Reloaded: A Structured Approach,
E. Zijlstra (2014)
10.2147/DDDT.S79322
Insulin administration: present strategies and future directions for a noninvasive (possibly more physiological) delivery
E. Matteucci (2015)
10.1016/j.jconrel.2014.03.013
A clinical update of using albumin as a drug vehicle - a commentary.
F. Kratz (2014)
10.1111/j.2042-7158.1991.tb05437.x
The Effect of Site of Administration in the Gastrointestinal Tract on the Absorption of Insulin from Nanocapsules in Diabetic Rats
C. Michel (1991)
10.2147/IJN.S57939
Tissue distribution and excretion kinetics of orally administered silica nanoparticles in rats
J. Lee (2014)
10.1038/clpt.2009.159
Orally Administered Glucagon‐Like Peptide‐1 Affects Glucose Homeostasis Following an Oral Glucose Tolerance Test in Healthy Male Subjects
R. Steinert (2009)
10.1016/S0378-5173(98)00288-9
The importance of intestinal residence time of absorption enhancer on drug absorption and implication on formulative considerations
Muhammad Baluom (1998)
10.2174/1567201053586001
Oral delivery of insulin with the eligen technology: mechanistic studies.
D. Malkov (2005)
10.1016/j.ejpb.2010.07.002
Microemulsions for oral delivery of insulin: design, development and evaluation in streptozotocin induced diabetic rats.
G. Sharma (2010)
10.1016/J.IJPHARM.2003.07.015
Calcium phosphate-PEG-insulin-casein (CAPIC) particles as oral delivery systems for insulin.
T. Morçöl (2004)
10.1002/(SICI)1098-1128(200003)20:2<169::AID-MED4>3.0.CO;2-0
The Development of Delivery Agents that Facilitate the Oral Absorption of Macromolecular Drugs
A. Leone-Bay (2000)
10.1507/ENDOCRJ1954.26.337
Effects of oral administration of positively charged insulin liposomes on alloxan diabetic rats: preliminary study.
A. Hashimoto (1979)
10.7573/dic.212283
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
Lalita Prasad-Reddy (2015)
10.1016/j.ejps.2008.12.017
Oral insulin delivery using nanoparticles based on microemulsions with different structure-types: optimisation and in vivo evaluation.
A. Graf (2009)
10.1007/s40265-015-0370-5
Albiglutide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
H. Blair (2015)
10.1016/J.EJPB.2004.03.023
Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs.
S. M. van der Merwe (2004)
10.1016/j.biotechadv.2014.07.006
A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules.
Bibi F Choonara (2014)
10.1016/j.ijpharm.2012.10.025
Integrity and stability of oral liposomes containing bile salts studied in simulated and ex vivo gastrointestinal media.
Shunwen Hu (2013)
10.1016/j.addr.2011.12.009
Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers.
Laura M Ensign (2012)
10.3109/02652040903515490
Insulin-S.O (sodium oleate) complex-loaded PLGA nanoparticles: Formulation, characterization and in vivo evaluation
S. Sun (2010)
10.2174/157339908784220741
Role of islet-, gut-, and adipocyte-derived hormones in the central control of food intake and body weight: implications for an integrated neurohormonal approach to obesity pharmacotherapy.
Hubert Chen (2008)
10.1016/j.jconrel.2012.05.040
Recent advances in nanocarrier-based mucosal delivery of biomolecules.
Olga Kammona (2012)
10.1021/BM700916H
Novel insulin thiomer nanoparticles: in vivo evaluation of an oral drug delivery system.
B. Deutel (2008)
10.1016/j.bpj.2010.01.012
Characterization of particle translocation through mucin hydrogels.
O. Lieleg (2010)
10.1016/j.amjmed.2014.07.006
New developments in insulin therapy for type 2 diabetes.
Christopher H. Sorli (2014)
10.1021/nl801736q
Microfluidic platform for controlled synthesis of polymeric nanoparticles.
R. Karnik (2008)
10.1016/j.ejps.2012.01.002
Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration.
X. Zhang (2012)
10.2174/1381612821666150416100943
Characterization of particulate drug delivery systems for oral delivery of Peptide and protein drugs.
Philip Carsten Christophersen (2015)
10.1016/j.ejpb.2015.01.023
Nanoparticle diffusion within intestinal mucus: Three-dimensional response analysis dissecting the impact of particle surface charge, size and heterogeneity across polyelectrolyte, pegylated and viral particles.
M. Abdulkarim (2015)
10.1111/j.1476-5381.2012.01911.x
The use of animal models in diabetes research
A. King (2012)
10.3109/10611869808995876
Absorption enhancement in intestinal epithelial Caco-2 monolayers by sodium caprate: assessment of molecular weight dependence and demonstration of transport routes.
T. Lindmark (1998)
10.1517/17425247.2014.917077
Oral peptide and protein delivery: intestinal obstacles and commercial prospects
Alice L Smart (2014)
10.3109/03639045.2010.497151
The influence of lipid characteristics on the formation, in vitro release, and in vivo absorption of protein-loaded SLN prepared by the double emulsion process
R. Yang (2011)
10.1016/S1773-2247(14)50002-0
Nanotechnologies in Drug Delivery - An Industrial Perspective
D. Bazile (2014)
10.1289/ehp.1306957
Toward Advancing Nano-Object Count Metrology: A Best Practice Framework
Scott Campbell Brown (2013)
10.7556/JAOA.2009.109.1.26
Insulin analog therapy: improving the match with physiologic insulin secretion.
J. Freeman (2009)
10.1152/PHYSREV.00034.2006
The physiology of glucagon-like peptide 1.
J. Holst (2007)
Eligen insulin--a system for the oral delivery of insulin for diabetes.
A. Hoffman (2008)
10.2147/IJN.S31711
Solid lipid nanoparticles modified with stearic acid–octaarginine for oral administration of insulin
Z. Zhang (2012)
10.1016/j.jconrel.2013.05.043
Can bioadhesive nanoparticles allow for more effective particle uptake from the small intestine?
J. Reineke (2013)
10.1016/S0006-3495(01)75844-4
Diffusion of macromolecules and virus-like particles in human cervical mucus.
S. S. Olmsted (2001)
10.1016/j.biomaterials.2013.01.064
Nanoparticle diffusion in respiratory mucus from humans without lung disease.
Benjamin S Schuster (2013)
10.1177/193229680900300322
Oral Insulin: The Rationale for This Approach and Current Developments
E. Arbit (2009)
10.1016/j.drudis.2014.01.011
Mucus models to evaluate nanomedicines for diffusion.
A. Groo (2014)
10.1081/DDC-100107680
Enhancement of Absorption of Insulin-Loaded Polyisobutylcyanoacrylate Nanospheres by Sodium Cholate After Oral and Subcutaneous Administration in Diabetic Rats
M. A. Radwan (2001)
10.1016/J.IJPHARM.2005.04.016
A lecithin-based microemulsion of rh-insulin with aprotinin for oral administration: Investigation of hypoglycemic effects in non-diabetic and STZ-induced diabetic rats.
A. Cilek (2005)
10.1210/JC.2002-021053
Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects.
T. Vilsbøll (2003)
10.1016/j.ijpharm.2011.12.055
HP55-coated capsule containing PLGA/RS nanoparticles for oral delivery of insulin.
Z. M. Wu (2012)
10.1517/17425247.2012.694865
Microemulsions for oral administration and their therapeutic applications
S. Gibaud (2012)
10.1242/jcs.02915
Myosin light chain phosphorylation regulates barrier function by remodeling tight junction structure
L. Shen (2006)
10.1016/j.biomaterials.2010.01.042
Enteric-coated capsules filled with freeze-dried chitosan/poly(gamma-glutamic acid) nanoparticles for oral insulin delivery.
K. Sonaje (2010)
10.1111/dom.12501
Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes?
P. Home (2015)
10.3109/10717540903223442
Influence of polymers ratio on insulin-loaded nanoparticles based on poly-ε-caprolactone and Eudragit® RS for oral administration
M. Socha (2009)
10.1210/EN.2003-0323
Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.
L. Farilla (2003)
10.1111/j.2042-7158.1989.tb06377.x
The Uptake and Translocation of Latex Nanospheres and Microspheres after Oral Administration to Rats
P. Jani (1989)
10.1002/jbm.b.31241
Synthesis and characterization of PEGylated calcium phosphate nanoparticles for oral insulin delivery.
Rukmani Ramachandran (2009)
10.1002/JPS.2600750311
Peptide-carrier interaction: induction of liposome fusion and aggregation by insulin.
J. Wiessner (1986)
Home, «Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes?,
P D. (2015)
10.1211/0022357021778736
In‐vitro release and oral bioactivity of insulin in diabetic rats using nanocapsules dispersed in biocompatible microemulsion
Suchat Watnasirichaikul (2002)
10.1016/j.ejim.2014.03.005
Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities.
A. Lund (2014)
10.1016/j.ejpb.2012.02.009
Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose.
M. Niu (2012)
10.1023/A:1016212804288
A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability
G. Amidon (2004)
10.1111/j.1463-1326.2011.01395.x
A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations
M. Evans (2011)
10.1097/00007611-200295010-00001
Diabetes mellitus.
M. D. De Luise (1993)
10.17221/7495-CJAS
Oral delivery of insulin-loaded nanoparticles in diabetic rabbits and in sheep
Stoilova Olya (2018)
10.1111/bcpt.12342
Mucus as a barrier to drug delivery – understanding and mimicking the barrier properties.
M. Boegh (2015)
10.3945/ajcn.2010.29663
Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects.
R. Steinert (2010)
10.1517/17425247.2014.924500
Orally active-targeted drug delivery systems for proteins and peptides
X. Li (2014)
10.1111/j.1463-1326.2009.01146.x
The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes
S. Luzio (2010)
10.1002/jps.21874
Poly(epsilon-caprolactone)/eudragit nanoparticles for oral delivery of aspart-insulin in the treatment of diabetes.
C. Damgé (2010)
10.2337/DIASPECT.17.3.183
Glucose Metabolism and Regulation: Beyond Insulin and Glucagon
S. Aronoff (2004)
10.1016/0304-4165(82)90267-7
Use of liposomes to aid intestinal absorption of entrapped insulin in normal and diabetic dogs.
H. M. Patel (1982)
10.1159/000179509
Orally administered liposome-entrapped insulin in diabetic animals. A critical assessment.
J. F. Arrieta-Molero (1982)
10.1016/j.addr.2008.11.002
Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues.
S. Lai (2009)
10.1073/pnas.0706473105
Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies
J. D. Roth (2008)
10.1080/10717540902937471
Insulin-loaded poly(acrylic acid)-cysteine nanoparticles: Stability studies towards digestive enzymes of the intestine
G. Perera (2009)
10.1016/J.EUPROT.2014.05.003
The emergence of peptides in the pharmaceutical business: From exploration to exploitation
T. Uhlig (2014)
10.1016/j.biomaterials.2013.08.048
Intestinal mucosa permeability following oral insulin delivery using core shell corona nanolipoparticles.
X. Li (2013)
10.3109/02652049409040461
Liposomes as a carrier for oral administration of insulin: effect of formulation factors.
K. B. Choudhari (1994)
10.1021/BM0607776
Preparation and characterization of nanoparticles shelled with chitosan for oral insulin delivery.
Yu-Hsin Lin (2007)
10.1208/s12249-011-9647-5
Chitosan–Sodium Lauryl Sulfate Nanoparticles as a Carrier System for the In Vivo Delivery of Oral Insulin
A. Elsayed (2011)
10.1371/journal.pone.0059524
Glucose-Reducing Effect of the ORMD-0801 Oral Insulin Preparation in Patients with Uncontrolled Type 1 Diabetes: A Pilot Study
R. Eldor (2013)
Shard, «Emerging Techniques for Submicrometer Particle Sizing Applied to St ber Silica,
N. ell (2012)
10.2147/IJN.S41457
Preparation, characterization, and in vitro and in vivo investigation of chitosan-coated poly (d,l-lactide-co-glycolide) nanoparticles for intestinal delivery of exendin-4
M. Wang (2013)
Editorial: Breaking the Skin Barrier: Achievements and the Future
Yasser Shahzad (1969)
10.1016/j.amjmed.2014.07.005
Evolution of insulin: from human to analog.
J. Tibaldi (2014)
Methods and compositions for oral administration
Miriam Kidron (2015)
10.1016/j.jconrel.2012.11.011
Calcium depletion-mediated protease inhibition and apical-junctional-complex disassembly via an EGTA-conjugated carrier for oral insulin delivery.
Er-Yuan Chuang (2013)
10.1016/0016-5085(85)90211-2
Human distribution and release of a putative new gut hormone, peptide YY.
T. Adrian (1985)
10.1016/j.brainres.2005.02.065
Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3–36) on food intake
C. R. Abbott (2005)
10.1007/S10404-013-1152-6
Mass production of highly monodisperse polymeric nanoparticles by parallel flow focusing system
Xianjie Kang (2013)
Raufman, «Isolation and Characterizationo f Exendin-4, an Exendin-3 Analogue from Heloderma suspecturn Venom,
J. Eng (1992)
10.1164/AJRCCM.162.5.9909009
Cystic fibrosis sputum: a barrier to the transport of nanospheres.
N. Sanders (2000)
10.1177/193229681300700228
Oral Insulin Delivery: How Far are We?
P. Fonte (2013)
10.1016/j.biomaterials.2011.08.087
A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery.
M. Chen (2011)
10.1016/J.IJPHARM.2004.10.003
Oral and subcutaneous absorption of insulin poly(isobutylcyanoacrylate) nanoparticles.
M. S. Mesiha (2005)
10.1111/j.2042-7158.1998.tb07136.x
Transepithelial Transport of Large Particles in Rat: a New Model for the Quantitative Study of Particle Uptake
J. Limpanussorn (1998)



This paper is referenced by
10.1016/j.addr.2018.12.001
Strategies for improving diabetic therapy via alternative administration routes that involve stimuli-responsive insulin-delivering systems.
Yu-Jung Lin (2018)
10.1080/17425247.2018.1503250
Silica nanoparticles on the oral delivery of insulin
Xinyi Tan (2018)
10.1016/j.apsb.2019.08.003
Recent progress in drug delivery
C. Li (2019)
10.1080/1061186X.2018.1561891
Nano-carriers for drug routeing – towards a new era
Harivardhan Reddy Lakkireddy (2019)
10.1080/21688370.2016.1187981
Introduction for the special issue on recent advances in drug delivery across tissue barriers
R. Mrsny (2016)
10.1007/s13346-018-0557-x
Intra-articular delivery of a nanocomplex comprising salmon calcitonin, hyaluronic acid, and chitosan using an equine model of joint inflammation
Svenja Sladek (2018)
10.1002/adma.201901935
Oral Delivery of Biologics for Precision Medicine.
M. Durán-Lobato (2019)
10.1016/j.jcis.2020.08.010
Zwitterion-functionalized mesoporous silica nanoparticles for enhancing oral delivery of protein drugs by overcoming multiple gastrointestinal barriers.
Y. Gao (2020)
10.1016/j.addr.2016.10.005
Oral delivery of peptides: opportunities and issues for translation.
D. Brayden (2016)
10.1016/j.xphs.2019.01.025
Overcoming Poor Tabletability of Bulky Absorption Enhancers by Spray Drying Technology.
Weiwei Fan (2019)
10.1016/j.bmc.2017.08.028
Peroral peptide delivery: Peptidase inhibition as a key concept for commercial drug products.
Martin Werle (2018)
10.1080/1061186X.2019.1588280
A journey through the emergence of nanomedicines with poly(alkylcyanoacrylate) based nanoparticles
Christine Vauthier (2019)
10.1016/j.biomaterials.2017.10.022
Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oral insulin delivery.
W. Fan (2018)
10.3390/pharmaceutics12070607
Development of Lipid–Polymer Hybrid Nanoparticles for Improving Oral Absorption of Enoxaparin
B. Tang (2020)
10.3390/pharmaceutics11010036
Intestinal Drug Absorption Enhancement by Aloe vera Gel and Whole Leaf Extract: In Vitro Investigations into the Mechanisms of Action
Anja Haasbroek (2019)
10.1016/j.ejpb.2018.09.023
Influence of the surface properties of nanocapsules on their interaction with intestinal barriers
Irene Santalices (2018)
10.1016/j.ijpharm.2017.11.051
Sustained-release multiparticulates for oral delivery of a novel peptidic ghrelin agonist: Formulation design and in vitro characterization.
Ken Howick (2018)
10.1016/j.matpr.2020.04.138
Development of nanoemulsion of Alginate/Aloe vera for oral delivery of insulin
Sabjan Khaleel Basha (2020)
10.1016/J.JDDST.2017.06.018
Advances on the formulation of proteins using nanotechnologies
Irene Santalices (2017)
10.1038/s41598-017-07949-4
Intestinal transepithelial permeability of oxytocin into the blood is dependent on the receptor for advanced glycation end products in mice
Haruhiro Higashida (2017)
10.1016/j.freeradbiomed.2017.02.049
Microvascular NADPH oxidase in health and disease
Y. Li (2017)
10.3390/pharmaceutics11020078
Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C10)
Caroline Twarog (2019)
10.1016/j.ijpharm.2017.07.001
Polyarginine nanocapsules: A versatile nanocarrier with potential in transmucosal drug delivery.
Ana Gonzalez-Paredes (2017)
Loading and coating of microcontainers for oral drug delivery
C. Mazzoni (2019)
10.1186/s12951-020-00619-0
Oral delivery of exenatide-loaded hybrid zein nanoparticles for stable blood glucose control and β-cell repair of type 2 diabetes mice
Xiaoyan Bao (2020)
10.1136/gutjnl-2019-319146
Novel strategy for oral peptide delivery in incretin-based diabetes treatment
Yining Xu (2019)
10.1126/sciadv.aba0145
Molecular targeting of FATP4 transporter for oral delivery of therapeutic peptide
Zhenhua Hu (2020)
Semantic Scholar Logo Some data provided by SemanticScholar